The Global Health Body Raises Concern Over Critical Lack of Weight-Loss Medications
Under one in 10 individuals who could benefit from weight-loss injections including Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance recognises that obesity is a chronic disease that can be treated with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are key hurdles to broad availability to the injections that can aid individuals in losing considerable weight, says the organization.
Skinny Jab Scarcity
Even under the present most optimistic scenario, the manufacturing of such drugs would only suffice for around 100 million people – less than 10% of eligible patients, per the WHO.
The guideline calls on governments and firms to expand access, by measures like licensing agreements.
A patent on semaglutide – the main component of the drug Wegovy – is due to expire in multiple nations in 2026.
The Way Weight-Loss Injections Operate
These medications mimick a biological compound to reduce digestion speed, curb appetite and increase the sense of being full so users eat less.
People usually begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Evidence points to users may regain a significant portion a year later of stopping the drug, as their normal appetite come back.
Being carrying excess weight raises your risk for developing medical conditions, like diabetes, heart disease, brain attack, and specific malignancies.
Obesity concerns individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.